Neuronetics 3Q 2026: Revenue $41.96M, Net income ($1.69M), EPS ($0.02) — 10-Q Summary
Neuronetics reported Q3 2026 revenue of $41.96M, up 12.5% YoY, with a net loss of $1.69M, improved from $9.05M. EPS loss was $0.02. Nine-month revenue rose 10% to $118.0M. Greenbrook clinics contributed 62% of Q3 revenue, growing 20%. NeuroStar revenue was $15.8M. Management expects Greenbrook growth and NeuroStar sales acceleration.
How this was made
The 30-second read
Why it matters
The Q3 earnings release shows revenue growth and a significant reduction in net loss, which could improve investor sentiment.
Market read
Micro‑cap earnings with better-than-expected loss narrowing may trigger modest price movement.
What to watch
Potential upcoming regulatory approvals or competitive pressures could offset short‑term gains.
Background
Neuronetics (NASDAQ:STIM) provides FDA‑cleared neurostimulation systems for treating depression and other disorders.
Ticker impact
Neuronetics reported Q3 2026 results with revenue up 12.5% YoY and net loss narrowing, marking the first public disclosure of these figures.
modest upside as investors price in narrowed loss and revenue growth
The company posted better-than-expected loss and revenue growth, which typically supports a short-term price rally for a micro‑cap.
Market effects
Improved results may signal strength in the neurostimulation device sector.
Limited to U.S. small‑cap biotech investors.
Low, as the company is a niche micro‑cap.
Counterpoint
Despite loss narrowing, the company remains unprofitable and may face cash‑flow constraints.
Key entities
- CompanyNeuronetics, Inc.
Neurostimulation device manufacturer.
